<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HESPAN- hetastarch and sodium chloride injection, solution </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use HESPAN® (6% HETASTARCH IN 0.9% SODIUM CHLORIDE INJECTION) safely and effectively. See full prescribing information for HESPAN® (6% HETASTARCH IN 0.9% SODIUM CHLORIDE INJECTION).<br><br>    HESPAN® (6% HETASTARCH IN 0.9% SODIUM CHLORIDE INJECTION) IN EXCEL® CONTAINER, for intravenous use<br>        Initial U.S. Approval: 1991    </div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:    MORTALITY <br>                      RENAL REPLACEMENT THERAPY</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li>
<span class="Bold">In critically ill adult patients, including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, use of hydroxyethyl starch (HES) products, including HESPAN®, increases risk of </span><ul>
<li><span class="Bold">Mortality</span></li>
<li><span class="Bold">Renal replacement therapy </span></li>
</ul>
</li>
<li><span class="Bold">Do not use HES products, including HESPAN®, in critically ill adult patients including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> </span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING:    MORTALITY <br>                      RENAL REPLACEMENT THERAPY</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li>
<span class="Bold">In critically ill adult patients, including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, use of hydroxyethyl starch (HES) products, including HESPAN®, increases risk of </span><ul>
<li><span class="Bold">Mortality</span></li>
<li><span class="Bold">Renal replacement therapy </span></li>
</ul>
</li>
<li><span class="Bold">Do not use HES products, including HESPAN®, in critically ill adult patients including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> </span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul>
<li>HESPAN® is a hetastarch indicated for treatment of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> when plasma volume expansion is desired. (<a href="#i4i_indications_id_9c155a88-2932-4322-bc4d-e87b9f21a344">1</a>)</li>
<li>HESPAN® in leukapheresis has shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means. (<a href="#i4i_indications_id_9c155a88-2932-4322-bc4d-e87b9f21a344">1</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"> <span class="Bold">For intravenous use only.</span> </p>
<a name="id_89a52682-d9ba-4ff2-838a-a939af0057de"></a><table>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><span class="Bold"> Recommended Dosage</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"> </td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Dose</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Adults (<a href="#i4i_section_id_72849d1b-183f-438a-a2e3-b82b8aba3963">2.1</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">500 to 1000 mL</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Leukapheresis (<a href="#i4i_section_id_951bf295-1936-49ec-9429-5a3536d5b38c">2.2</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">250 to 700 mL of HESPAN® (6% hetastarch in 0.9% sodium chloride injection) with citrate anticoagulant is added to the input line of the centrifugation apparatus.</td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>30 g hetastarch in 500 mL 0.9% sodium chloride injection. (<a href="#i4i_dosage_form_strength_id_e314dde4-d441-4349-b43c-d2b496c0dd4c">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Do not use hydroxyethyl starch (HES) products, including HESPAN®, in critically ill adult patients, including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, due to increased risk of mortality and renal replacement therapy (RRT). (<a href="#i4i_contraindications_id_6b5473bd-e058-4eee-be71-48512dc68b62">4</a>) </li>
<li>Do not use HES products, including HESPAN®, in patients with severe liver disease (<a href="#i4i_contraindications_id_6b5473bd-e058-4eee-be71-48512dc68b62">4</a>) </li>
<li>Do not use HES products, including HESPAN®, in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydroxyethyl starch (<a href="#i4i_contraindications_id_6b5473bd-e058-4eee-be71-48512dc68b62">4</a>) </li>
<li>Do not use HES products, including HESPAN®, in clinical conditions where volume overload is a potential problem. (<a href="#i4i_contraindications_id_6b5473bd-e058-4eee-be71-48512dc68b62">4</a>) </li>
<li>Do not use HES products, including HESPAN®, in patients with pre-existing coagulation or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders (<a href="#i4i_contraindications_id_6b5473bd-e058-4eee-be71-48512dc68b62">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Avoid use in patients with pre-existing renal dysfunction (<a href="#i4i_section_id_d88b5da0-988c-473d-af29-c2a19502dcd2">5.1</a>) </li>
<li>Discontinue use of HESPAN® at the first sign of <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span> (<a href="#i4i_section_id_d88b5da0-988c-473d-af29-c2a19502dcd2">5.1</a>) </li>
<li>Continue to monitor renal function in hospitalized patients for at least 90 days as use of RRT has been reported up to 90 days after administration of HES products, including HESPAN® (<a href="#i4i_section_id_d88b5da0-988c-473d-af29-c2a19502dcd2">5.1</a>) </li>
<li>HESPAN® is not recommended for use as a cardiac bypass pump prime, while the patient is on cardiopulmonary bypass, or in the immediate period after the pump has been discontinued because of the risk of increasing coagulation abnormalities and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients whose coagulation status is already impaired. Discontinue use of HESPAN® at first sign of <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> (<a href="#i4i_section_id_4ada0eee-8430-47eb-b0b7-d493ef85da12">5.2</a>) <p class="Highlighta">Monitor liver function in patients receiving HES products, including HESPAN® (<a href="#i4i_section_id_4ada0eee-8430-47eb-b0b7-d493ef85da12">5.2</a>) </p>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>The serious adverse events reported in clinical trials are Increased mortality and renal replacement therapy in critically ill patients (<a href="#i4i_section_id_58323e63-4e62-48e2-9c82-95385514de47">6.1</a>) </li>
<li>Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, hemodilution, circulatory overload and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. (<a href="#i4i_section_id_04bdbff5-b47b-4dbf-8d59-48f5a2534eed">6.2</a>) </li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact B. Braun Medical Inc. at 1-800-227-2862 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Use with caution with drugs that negatively influence the coagulation system. (<a href="#i4i_interactions_id_146cd424-c7e7-43d1-addd-6ac4b4dca7c2">7</a>) </li>
<li>The safety and compatibility of other additives have not been established. (<a href="#i4i_interactions_id_146cd424-c7e7-43d1-addd-6ac4b4dca7c2">7</a>)</li>
</ul></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 7/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Leukapheresis</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Direction for use for HESPAN®</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Renal Dysfunction</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Circulatory Overload</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Liver Function Test</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">Surgical Patients Comparative Studies</a></h2>
<h2><a href="#section-12.2" class="toc">Pediatric Postoperative Volume Expander Study</a></h2>
<h2><a href="#section-12.3" class="toc">Adult Critically Ill Studies</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_6667a69d-964f-4600-a995-1029df8b4235"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">WARNING:        MORTALITY <br>                          RENAL REPLACEMENT THERAPY</span></p>
<ul>
<li>
<span class="Bold">In critically ill adult patients, including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, use of hydroxyethyl starch (HES) products, including HESPAN®, increases risk of </span><ul>
<li><span class="Bold">Mortality</span></li>
<li><span class="Bold">Renal replacement therapy </span></li>
</ul>
</li>
<li><span class="Bold">Do not use HES products, including HESPAN®, in critically ill adult patients including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> </span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_9c155a88-2932-4322-bc4d-e87b9f21a344"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">HESPAN® is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> when plasma volume expansion is desired. It is not a substitute for blood or plasma.</p>
<p>The adjunctive use of HESPAN® in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b0e4c77e-dd50-490c-acd2-5f97617f2d71"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Italics">Dosage for Acute Use in Plasma Volume Expansion</span></span></p>
<p>HESPAN® is administered by intravenous infusion only. Total dosage and rate of infusion depend upon the amount of blood or plasma lost and the resultant hemoconcentration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_72849d1b-183f-438a-a2e3-b82b8aba3963"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adults</h2>
<p class="First">The amount usually administered is 500 to 1000 mL. Doses of more than 1500 mL per day for the typical 70 kg patient (approximately 20 mL per kg of body weight) are usually not required. Higher doses have been reported in postoperative and <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> patients where severe blood loss has occurred [see <span class="Italics"><a href="#i4i_warnings_precautions_id_99556bac-e1ac-4b7c-a831-ab80e204665d">Warnings and Precautions (5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_951bf295-1936-49ec-9429-5a3536d5b38c"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Leukapheresis</h2>
<p class="First">250 to 700 mL of HESPAN® (6% hetastarch in 0.9% sodium chloride injection) with citrate anticoagulant is administered by aseptic addition to the input line of the centrifugation apparatus at a ratio of 1:8 to 1:13 to venous whole blood. The HESPAN® and citrate should be thoroughly mixed to assure effective anticoagulation of blood as it flows through the leukapheresis machine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_21988c74-bf8b-4a06-a4ba-8352fd355ddb"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Direction for use for HESPAN®</h2>
<ul>
<li>Do not use plastic container in series connection. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> may result. If administration is not controlled by a pumping device, refrain from applying excessive pressure (&gt;300mmHg) causing distortion to the container such as wringing or twisting. Such handling could result in breakage of the container.</li>
<li>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use only if solution is clear and container and seals are intact.</li>
<li>Intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours. </li>
<li>Withdraw or expel all air from the bag through the medication port prior to infusion if administration is by pressure infusion. <p class="First">For single use only. Discard unused portion.</p>
</li>
</ul>
<p class="First"><span class="Bold">CAUTION:  Before administering to the patient, review these directions:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_976f21c8-4d11-457f-9def-758aac3f8498"></a><a name="section-2.3.1"></a><p></p>
<h3>Visual Inspection</h3>
<ul>
<li>Do not remove the plastic infusion container from its overwrap until immediately before use. </li>
<li>Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date. </li>
<li>Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. </li>
<li>Any container which is suspect should not be used.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_98335afb-b25b-4307-b668-0f698119abaf"></a><a name="section-2.3.2"></a><p></p>
<h3>To Open</h3>
<ol>
<li>Tear overwrap down at notch and remove solution container. </li>
<li>Check for minute leaks by squeezing solution container firmly. </li>
<li>If any leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65462c65-94cd-4a4a-b795-c3996f58d393"></a><a name="section-2.3.3"></a><p></p>
<h3>Preparation for Administration</h3>
<ol>
<li>Remove plastic protector from sterile set port at bottom of container. </li>
<li>Attach administration set. Refer to complete directions accompanying set.</li>
</ol>
<p class="First">When stored at room temperature, HESPAN® admixtures of 500-560 mL with citrate concentrations up to 2.5% were compatible for 24 hours. The safety and compatibility of additives other than citrate have not been established.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_e314dde4-d441-4349-b43c-d2b496c0dd4c"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"> Single-use container:</p>
<ul><li>30 g hetastarch in 500 mL of 0.9% sodium chloride injection.</li></ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6b5473bd-e058-4eee-be71-48512dc68b62"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul>
<li>Do not use hydroxyethyl starch (HES) products, including HESPAN®, in critically ill adult patients, including patients with <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, due to increased risk of mortality and renal replacement therapy (RRT). </li>
<li>Do not use HES products, including HESPAN®, in patients with severe liver disease </li>
<li>Do not use HES products, including HESPAN®, in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydroxyethyl starch </li>
<li>Do not use HES products, including HESPAN®, in clinical conditions where volume overload is a potential problem (such as, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> not related to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>). </li>
<li>Do not use HES products, including HESPAN®, in patients with pre-existing coagulation or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_99556bac-e1ac-4b7c-a831-ab80e204665d"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d88b5da0-988c-473d-af29-c2a19502dcd2"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Renal Dysfunction</h2>
<ul>
<li>Avoid use in patients with pre-existing renal dysfunction </li>
<li>Discontinue use of HESPAN® at the first sign of <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span> </li>
<li>Continue to monitor renal function in hospitalized patients for at least 90 days as use of RRT has been reported up to 90 days after administration of HES products, including HESPAN®</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ada0eee-8430-47eb-b0b7-d493ef85da12"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Coagulopathy</span></h2>
<ul><li>HESPAN® is not recommended for use as a cardiac bypass pump prime, while the patient is on cardiopulmonary bypass, or in the immediate period after the pump has been discontinued because of the risk of increasing coagulation abnormalities and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients whose coagulation status is already impaired. Discontinue use of HESPAN® at first sign of <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span><span class="Sup">1-2</span>
</li></ul>
<p class="First">HESPAN® has not been adequately evaluated to establish its safety in uses over extended periods other than leukapheresis. HESPAN®  has been associated with coagulation abnormalities in conjunction with an acquired, reversible von Willebrand’s-like syndrome and/or  Factor Vlll deficiency when used over a period of days. Replacement therapy should be considered if a severe Factor Vlll  deficiency is identified. If a <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> develops, it may take several days to resolve. Certain conditions may affect the safe  use of HESPAN® on a chronic basis. For example, in patients with <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span> where HESPAN® is used repeatedly over a period of days for the prevention of cerebral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, significant clinical <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may occur. Intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported.<span class="Sup">3</span></p>
<p>Slight declines in platelet counts and hemoglobin levels have been observed in donors undergoing repeated leukapheresis procedures using HESPAN® due to the volume expanding effects of hetastarch and to the collection of platelets and erythrocytes. Hemoglobin levels usually return to normal within 24 hours. Hemodilution by HESPAN® may also result in 24 hour declines of total protein, albumin, calcium, and fibrinogen levels. Regular and frequent clinical evaluation and complete blood counts (CBC) are necessary for proper monitoring of HESPAN® use during leukapheresis. If the frequency of leukapheresis is to exceed the guidelines for whole blood donation, you may wish to  consider the following additional tests: total leukocyte and platelet counts, leukocyte differential count, hemoglobin and hematocrit, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT), and partial thromboplastin time (PTT).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3efc3da-e8a4-4bda-8c4b-28a696fee484"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Life threatening anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been rarely reported with HESPAN®. Patients may develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to corn starch from which this product is made. If a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs, administration of the drug should be discontinued immediately and the appropriate treatment and supportive measures should be undertaken until symptoms have resolved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79901604-135e-4e87-ba77-346d4e30e88a"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Circulatory Overload</h2>
<p class="First">HESPAN® has not been adequately evaluated to establish its safety in situations other than treatment of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> in elective surgery.</p>
<p>Large volumes of HESPAN® may transiently alter the coagulation mechanism due to hemodilution and a direct inhibitory action on Factor Vlll. Administration of volumes of HESPAN® that are greater than 25% of the blood volume in less than 24 hours may cause significant hemodilution reflected by lower hematocrit and plasma protein values. Administration of packed red cells, platelets, or fresh frozen plasma should be considered if clinically indicated.</p>
<p>When using HESPAN® for plasma volume expansion, caution should be taken to avoid excessive hemodilution and circulatory overload especially in those patients at risk for developing <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>. HESPAN® is primarily excreted via the kidneys so caution should be exercised in patients who have <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Although the risk of circulatory overload is largely dependent on the clinical circumstances, use of doses higher than 20 mL/kg/24h will increase the risk significantly. Increased risk of coagulation abnormalities and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is also associated with higher doses. Monitor patients' vital signs and hemoglobin, hematocrit, platelet count, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time and partial thromboplastin time. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de1d49aa-86af-4b64-be74-a5c6d35e6bf1"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Liver Function Test</h2>
<ul><li>Monitor liver function in patients receiving HES products, including HESPAN®</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdc300a4-1a88-47ba-9c35-ac3f0fa109b5"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Drug/Laboratory Test Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d8e474d-8299-4091-8e31-970699f698b6"></a><a name="section-5.6.1"></a><p></p>
<h3><span class="Underline">Bilirubin Levels</span></h3>
<p class="First">Indirect bilirubin levels of 8.3 mg/L (normal 0.0-7.0 mg/L) have been reported in 2 out of 20 normal subjects who received multiple infusions of HESPAN® (6% hetastarch in 0.9% sodium chloride injection). Total bilirubin was within normal limits at all times; indirect bilirubin returned to normal by 96 hours following the final infusion. The significance, if any, of these elevations is not known; however, caution should be observed before administering HESPAN® to patients with a history of liver disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_acd23cfd-60b3-4f9d-9c6b-fbbb3c40c42f"></a><a name="section-5.6.2"></a><p></p>
<h3><span class="Underline">Serum Amylase Levels</span></h3>
<p class="First">Elevated serum amylase levels may be observed temporarily following administration of HESPAN® although no association with <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> has been demonstrated. Serum amylase levels cannot be used to assess or to evaluate for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> for 3-5 days after administration of HESPAN®. Elevated serum amylase levels persist for longer periods of time in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Hetastarch has not been shown to increase serum lipase.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f28799d2-bbd8-4a46-9199-36146e85489d"></a><a name="section-5.6.3"></a><p></p>
<h3><span class="Underline">Hemodialysis</span></h3>
<p class="First">HESPAN® is not eliminated by hemodialysis. The utility of other extracorporeal elimination techniques has not been evaluated.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d248498b-786b-45a7-8ae0-022d28d9d761"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The serious adverse events reported in clinical trials are increased mortality and renal replacement therapy renal in critically ill patients. </p>
<p>Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, hemodilution, circulatory overload and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58323e63-4e62-48e2-9c82-95385514de47"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Three randomized controlled trials (RCTs) followed critically ill adult patients treated with different HES products for 90 days.</p>
<p>One trial (N=804) in severe <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> patients using HES product (not approved in the U.S.) reported increased mortality (relative risk, 1.17; 95% CI, 1.01 to 1.36; p=0.03) and RRT (relative risk, 1.35; 95% CI, 1.01 to 1.80; p=0.04) in the HES treatment arm.<span class="Sup">4</span></p>
<p>Another trial (N=196) using different HES in severe <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> patients reported no difference in mortality (relative risk,1.20; 95% CI, 0.83 to 1.74; p=0.33) and a trend for RRT (relative risk, 1.83; 95% CI, 0.93 to 3.59; p=0.06) in HES patients.<span class="Sup">5</span></p>
<p>A third trial (N=7000) using different HES in a heterogeneous patient population consisting of critically ill adult patients admitted to the ICU reported no difference in mortality (relative risk, 1.06; 95% CI, 0.96 to 1.18; p=0.26) but increased use of RRT (relative risk, 1.21; 95% CI, 1.00 to 1.45; p=0.04) in HES patients.<span class="Sup">6</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_04bdbff5-b47b-4dbf-8d59-48f5a2534eed"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Because adverse reactions are reported voluntarily post-approval from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.</p>
<p>The following adverse reactions have been identified and reported during the post-approval use of HES products:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c442efde-7359-46a8-a5f3-e8ea23d0bc7c"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Underline">Mortality</span></h3>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac0cb6d9-0318-430b-8d96-0e8f70c6923a"></a><a name="section-6.2.2"></a><p></p>
<h3><span class="Underline">Renal</span></h3>
<p class="First">need for renal replacement therapy</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e3984735-8ce8-4ba9-9b05-aaeb8867ecd2"></a><a name="section-6.2.3"></a><p></p>
<h3><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></span></h3>
<p class="First">including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, life-threatening anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, non-cardiac <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, facial and <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [see <span class="Italics"><a href="#i4i_section_id_e3efc3da-e8a4-4bda-8c4b-28a696fee484">Warnings and Precautions (5.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_29366c0a-0365-4862-9f29-591d9d9b5ae4"></a><a name="section-6.2.4"></a><p></p>
<h3><span class="Underline">Cardiovascular reactions</span></h3>
<p class="First">including circulatory overload, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> [see <span class="Italics"><a href="#i4i_section_id_79901604-135e-4e87-ba77-346d4e30e88a">Warnings and Precautions (5.4)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ffa21f0-1265-4d7f-b413-5e7a1d330c4c"></a><a name="section-6.2.5"></a><p></p>
<h3><span class="Underline">Hematologic reactions</span></h3>
<p class="First">including intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to hemodilution [see <span class="Italics"><a href="#i4i_section_id_79901604-135e-4e87-ba77-346d4e30e88a">Warnings and Precautions (5.4)</a></span>] and/or Factor Vlll deficiency, acquired von Willebrand’s-like syndrome, and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> including rare cases of disseminated intravascular <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span> and <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e10d5fab-ceed-427a-be56-b407c6f045a3"></a><a name="section-6.2.6"></a><p></p>
<h3><span class="Underline">Metabolic reactions</span></h3>
<p class="First">including <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ce4e0ef-1089-4dab-bbd9-a16f16bbbf49"></a><a name="section-6.2.7"></a><p></p>
<h3><span class="Underline">Other reactions</span></h3>
<p class="First">including <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> of the lower extremities, submaxillary and parotid glandular enlargement, mild <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span>. Hydroxyethyl starch-associated <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> has been reported in some patients with deposits of hydroxyethyl starch in peripheral nerves.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_146cd424-c7e7-43d1-addd-6ac4b4dca7c2"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">HESPAN® should be used with caution in patients who have been anticoagulated with other drugs that negatively influence the coagulation system.</p>
<ul><li>The safety and compatibility of other additives have not been established.</li></ul>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_ca4874f8-633d-4edb-af46-6baf7e28b170"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_50748210-2508-4f3b-a3b2-c13ff4bfcbc0"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Hetastarch has been shown to have an embryocidal effect on New Zealand rabbits when given intravenously over the entire organogenesis period in a daily dose 1/2 times the maximum recommended therapeutic human dose (1500 mL) and on BD rats when given intraperitoneally, from the 16th to the 21st day of pregnancy, in a daily dose 2.3 times the maximum recommended therapeutic human dose. When hetastarch was administered to New Zealand rabbits, BD rats, and swiss mice with intravenous daily doses of 2 times, 1/3 times, and 1 times the maximum recommended therapeutic human dose respectively over several days during the period of gestation, no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was evident<span class="Italics">.</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. HESPAN® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2ded443-9c02-4d74-81e4-5b6b8c58fdb3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether hetastarch is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when HESPAN® is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4154b35f-7f85-434f-89c5-0ea41dd0b7cf"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of hetastarch in pediatric patients have not been established. Adequate, well-controlled clinical trials to establish the safety and effectiveness of HESPAN® in pediatric patients have not been conducted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d4888577-db5a-41e4-8c31-301629673d4d"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">HESPAN® (6% hetastarch in 0.9% sodium chloride injection) is a sterile, nonpyrogenic solution for intravenous administration. </p>
<p>Each 100 mL contains:</p>
<p>Hetastarch.................................................. 6 g</p>
<p>Sodium Chloride, USP............................... 0.9 g</p>
<p>Water for Injection, USP............................. qs</p>
<p>pH adjusted with Sodium Hydroxide, NF if necessary</p>
<p>Concentration of Electrolytes (mEq/L): Sodium 154, Chloride 154</p>
<p>pH: approximately 5.9 with negligible buffering capacity</p>
<p>Calc. Osmolarity: approximately 309 mOsM</p>
<p>Hetastarch is a synthetic colloid derived from a waxy starch composed almost entirely of amylopectin. Hydroxyethyl ether groups are introduced into the glucose units of the starch, and the resultant material is hydrolyzed to yield a product with a molecular weight suitable for use as a plasma volume expander and erythrocyte sedimenting agent. The molar substitution is approximately 0.75 which means hetastarch has an average of approximately 75 hydroxyethyl groups for every 100 glucose units. The weight average molecular weight is approximately 600,000 with a range of 450,000 to 800,000 and with at least 80% of the polymers <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> within the range of 20,000 to 2,600,000. Hydroxyethyl groups are attached by ether linkage primarily at C-2 of the glucose unit and to a lesser extent at C-3 and C-6. The polymer resembles glycogen, and the polymerized D-glucose units are joined primarily by α-1,4 linkages with occasional α-1,6 branching linkages.</p>
<p>The chemical name for hetastarch is hydroxyethyl starch.</p>
<p>The structural formula is as follows:</p>
<div class="Figure"><img alt="HESPAN structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d1c2560-f289-49a9-9471-71199492fd8e&amp;name=6d1c2560-f289-49a9-9471-71199492fd8e-01.jpg"></div>
<p>Amylopectin derivative in which R<span class="Sub">2</span> and R<span class="Sub">3 </span>are H or CH<span class="Sub">2</span>CH<span class="Sub">2</span>OH and R<span class="Sub">6</span> is H, CH<span class="Sub">2</span>CH<span class="Sub">2</span>OH, or a branching point in the starch polymer connected through an α-1,6 link to additional D-glucopyranosyl units.</p>
<p>HESPAN® is a clear, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow to amber solution. Exposure to prolonged adverse storage conditions may result in a change to a turbid deep brown or the formation of a crystalline precipitate. Do not use the solution if these conditions are evident.</p>
<p>Not made with natural rubber latex, PVC or DEHP.</p>
<p>The plastic container is made from a multi-layered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.</p>
<p>The closure system has two ports; the one for the administration set has a tamper evident plastic protector.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_3d7ea5ac-742f-4671-9f40-f149ba5aa6ac"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_12a145da-38bf-454a-b8d6-51a06c9d8c6e"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The plasma volume expansion produced by HESPAN® approximates that of 5% Albumin (Human). Intravenous infusion of HESPAN® results in expansion of plasma volume.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_4a55e731-a697-46b5-b85a-456f0a0ed8a2"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">HESPAN® results in expansion of plasma volume that decreases over the succeeding 24 to 36 hours. The degree of plasma volume expansion and improvement in hemodynamic state depend upon the patient’s intravascular status.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d80bfdc9-a10e-476e-8cbb-2a0e9e93fafc"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Hetastarch molecules below 50,000 molecular weight are rapidly eliminated by renal excretion. A single dose of approximately 500 mL of HESPAN® (approximately 30 g) results in elimination in the urine of approximately 33% of the dose within 24 hours. This is a variable process but generally results in an intravascular hetastarch concentration of less than 10% of the total dose injected by two weeks. A study of the biliary excretion of HESPAN® in 10 healthy males accounted for less than 1% of the dose over a 14 day period. The hydroxyethyl group is not cleaved by the body but remains intact and attached to glucose units when excreted. Significant quantities of glucose are not produced as hydroxyethylation prevents complete metabolism of the smaller polymers.</p>
<p>The addition of hetastarch to whole blood increases the <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span>. Therefore, HESPAN® is used to improve the efficiency of granulocyte collection by centrifugal means.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_54451e7e-0f33-48a6-b110-b929b3288da7"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_fcc0bfd9-5d55-46e6-a9c0-2815ebec81aa"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies of animals have not been performed to evaluate the carcinogenic potential of hetastarch.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_af3b8ae4-5f53-40f1-b761-86729ec03651"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ba1c731-0ca0-41ed-a25f-35706d6412db"></a><a name="section-12.1"></a><p></p>
<h2>Surgical Patients Comparative Studies</h2>
<p class="First">In randomized, controlled, comparative studies of HESPAN® (6% hetastarch in 0.9% sodium chloride injection) (n=92) and Albumin (n=85) in surgical patients, no patient in either treatment group had a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complication and no significant difference was found in the amount of blood loss between the treatment groups.<span class="Sup">7-10</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1e0e57c-d4b4-4931-9cca-102d0f0eccf1"></a><a name="section-12.2"></a><p></p>
<h2>Pediatric Postoperative Volume Expander Study</h2>
<p class="First">In one small double-blind study, 47 infants, children, and adolescents (ages 1 year to 15.5 years) scheduled for repair of congenital heart disease with moderate <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> were randomized to receive either HESPAN® or Albumin as a postoperative volume expander during the first 24 hours after surgery. Thirty-eight children required colloid replacement therapy, of which 20 children received HESPAN®. No differences were found in the coagulation parameters or in the amount of replacement fluids required in the children receiving 20 mL/kg or less of either colloid replacement therapy. In children who received greater than 20 mL/kg of HESPAN®, an increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time was demonstrated (p=0.006).<span class="Sup">11 </span>There were no neonates included in this study [see <span class="Italics"><a href="#i4i_section_id_4154b35f-7f85-434f-89c5-0ea41dd0b7cf">Use in Specific Populations (8.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ad6507f-0128-4454-b572-05b44aedafb4"></a><a name="section-12.3"></a><p></p>
<h2>Adult Critically Ill Studies</h2>
<p class="First">Three randomized controlled trials (RCTs) followed critically ill adult patients treated with different HES products for 90 days.</p>
<p>One trial (N=804) in severe <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> patients using HES product (not approved in the U.S.) reported increased mortality (relative risk, 1.17; 95% CI, 1.01 to 1.36; p=0.03) and RRT (relative risk, 1.35; 95% CI, 1.01 to 1.80; p=0.04) in the HES treatment arm.<span class="Sup">4</span></p>
<p>Another trial (N=196) using different HES in severe <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> patients reported no difference in mortality (relative risk,1.20; 95% CI, 0.83 to 1.74; p=0.33) and a trend for RRT (relative risk, 1.83; 95% CI, 0.93 to 3.59; p=0.06) in HES patients.<span class="Sup">5</span></p>
<p>A third trial (N=7000) using different HES in a heterogeneous patient population consisting of critically ill adult patients admitted to the ICU reported no difference in mortality (relative risk, 1.06; 95% CI, 0.96 to 1.18; p=0.26) but increased use of RRT (relative risk, 1.21; 95% CI, 1.00 to 1.45; p=0.04) in HES patients.<span class="Sup">6</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_c12d3a48-a4f5-4329-a352-fc8756bb8686"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>Knutson JE., et al., Does Intraoperative Hetastarch Administration Increase Blood Loss and Transfusion Requirements After Cardiac Surgery? <span class="Italics">Anesthesia Analg</span>., 2000;90:801-7.</li>
<li>Cope JT., et al., Intraoperative Hetastarch Infusion Impairs Hemostasis After Cardiac Operations. <span class="Italics">The Annals of Thoracic Surgery</span>, 1997;63:78-83.</li>
<li>Damon L., Intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> During Treatment with Hydroxyethyl Starch. <span class="Italics">New England Journal of Medicine</span>, 1987;317(15):964-965.</li>
<li>Perner A, et al., Hydroxyethyl starch 130/0.42 versus Ringer"s acetate in severe <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> patients. <span class="Italics">The New England Journal of Medicine</span>, 2012 July 12;367(2):124-34.</li>
<li>Guidet B, et al., Assessment of hemodynamic efficacy and safety of 6% hydroxyethyl starch 130/0.4 vs 0.9% NaCl fluid replacement in patients with severe <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>: The CRYSTMAS Study. <span class="Italics">Critical Care</span>, 2012 May 24;16(3):R94.</li>
<li>Myburgh JA, et al., Hydroxyethyl starch or saline for fluid resuscitation in intensive care. <span class="Italics">The New England Journal of Medicine</span>, 2012 November 15;367(20):1901-11.</li>
<li>Diehl J., et al., Clinical Comparison of Hetastarch and Albumin in Postoperative Cardiac Patients. <span class="Italics">The Annals of Thoracic Surgery</span>, 1982;34(6):674-679.</li>
<li>Gold M., et al., Comparison of Hetastarch to Albumin for Perioperative <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> in Patients Undergoing <span class="product-label-link" type="condition" conceptid="198177" conceptname="Abdominal aortic aneurysm">Abdominal Aortic Aneurysm</span> Surgery. <span class="Italics">Annals of Surgery</span>, 1990;211(4):482-485.</li>
<li>Kirklin J., et al., Hydroxyethyl Starch versus Albumin for Colloid Infusion Following Cardiopulmonary Bypass in Patients Undergoing Myocardial Revascularization. <span class="Italics">The Annals of Thoracic Surgery</span>, 1984;37(1):40-46.</li>
<li>Moggio RA., et al., Hemodynamic Comparison of Albumin and Hydroxyethyl Starch in Postoperative Cardiac Surgery Patients. <span class="Italics">Critical Care Medicine</span>, 1983;11(12):943-945.</li>
<li>Brutocao D., et al., Comparison of Hetastarch with Albumin for Postoperative Volume Expansion in Children After Cardiopulmonary Bypass. <span class="Italics">Journal of Cardiothoracic and Vascular Anesthesia</span>, 1996;10(3):348-351.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_84bf8ebb-2d90-43d2-9899-415f79adce46"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">HESPAN® (6% hetastarch in 0.9% sodium chloride injection) is supplied sterile and nonpyrogenic in 500 mL EXCEL® Containers packaged 12 per case.</p>
<p><span class="Underline">NDC</span><span class="Bold">                        </span><span class="Underline">REF</span><span class="Bold">                          </span><span class="Underline">Volume<br></span>0264-1965-10         L6511                       500 mL</p>
<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. </p>
<p>Store at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.</p>
<p>Storage in automated dispensing machines: Brief exposure up to 2 weeks to ultraviolet or fluorescent light does not adversely affect the product labeling legibility; prolonged exposure can cause fading of the red label. Rotate stock frequently.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ef13fd1-bb39-460b-82a6-5ecd5d9f4895"></a><a name="section-15"></a><p></p>
<p class="First">Rx only</p>
<p><span class="Bold">&lt;p&gt;</span>Not made with natural rubber latex, DEHP or PVC.<span class="Bold">&lt;/p&gt;</span></p>
<p>EXCEL and HESPAN are registered trademarks of B. Braun Medical Inc.</p>
<p><span class="Bold">B. Braun Medical Inc.<br><span class="Bold">&lt;graphic&gt;<img alt="Recycle symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d1c2560-f289-49a9-9471-71199492fd8e&amp;name=6d1c2560-f289-49a9-9471-71199492fd8e-02.jpg">&lt;/graphic&gt;</span><span class="Bold">&lt;break&gt;<br>&lt;/break&gt;</span></span>Bethlehem, PA 18018-3524 USA<br>1-800-227-2862<br> www.bbraun.com <br>Made in USA</p>
<p>Y36-002-841  LD-233-2</p>
<p><span class="Bold">&lt;p&gt;</span>Repackaged by Cardinal Health<span class="Bold">&lt;/p&gt;</span></p>
<p><span class="Bold">&lt;p&gt;</span>Zanesville, OH 43701<span class="Bold">&lt;/p&gt;</span></p>
<p><span class="Bold">&lt;p&gt;</span>LA64441213<span class="Bold">&lt;/p&gt;</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_9bbe4242-062e-4cfb-9154-856b72d6887d"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">HESPAN 500 mL</p>
<p>(6% Hetastarch in 0.9%</p>
<p>Sodium Chloride Injection)</p>
<p>1 x  500 mL EXCEL CONTAINER</p>
<div class="Figure"><img alt="Bag Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d1c2560-f289-49a9-9471-71199492fd8e&amp;name=6d1c2560-f289-49a9-9471-71199492fd8e-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HESPAN 		
					</strong><br><span class="contentTableReg">hetastarch in sodium chloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-5178(NDC:0264-1965)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HETASTARCH</strong> (HETASTARCH) </td>
<td class="formItem">HETASTARCH</td>
<td class="formItem">6 g  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM CHLORIDE</strong> (SODIUM CATION and CHLORIDE ION) </td>
<td class="formItem">SODIUM CHLORIDE</td>
<td class="formItem">0.9 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-5178-8</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">500 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA890105</td>
<td class="formItem">04/04/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-5178)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6d1c2560-f289-49a9-9471-71199492fd8e</div>
<div>Set id: 6d1c2560-f289-49a9-9471-71199492fd8e</div>
<div>Version: 1</div>
<div>Effective Time: 20140129</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
